Abstract Wixela® Inhub® is the first therapeutically equivalent, substitutable generic version
of Advair Diskus®(fluticasone propionate/salmeterol) approved for the treatment of asthma …

Background: Wixela® Inhub® is a dry powder inhaler approved as a generic equivalent to
Advair® Diskus®(fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients …

Both asthma and chronic obstructive pulmonary disease (COPD) are inflammatory chronic
respiratory conditions with high rates of morbidity and mortality worldwide. The objectives of …

The novel, easy-to-use, breath-actuated fluticasone propionate/salmeterol multidose dry
powder inhaler (MDPI)(AirDuo RespiClick®) was recently approved in the USA for twice …

Purpose The purpose of this review is to discuss the development of Wixela™ Inhub™, a
generic equivalent of Advair Diskus®, a fixed-dose combination of fluticasone …

RATIONALE Wixela Inhub is a fluticasone propionate/salmeterol dry powder inhaler
developed in three strengths (100/50, 250/50, and 500/50 µg) as a generic equivalent of …

Fluticasone furoate/vilanterol [Relvar®, Revinty®(EU); Breo®(USA)], a fixed-dose
combination of an inhaled corticosteroid (ICS) and a long-acting β2-adrenoreceptor agonist …

PURPOSE: OT329 Solis® 100/50 (Oriel Therapeutics, Morrisville, NC, USA) was developed
as a fully substitutable generic to Advair Diskus® 100/50 (GSK, Research Triangle Park, NC …

Background: A novel multidose dry powder inhaler (MDPI) that is breath actuated, easy, and
intuitive to use has been developed for administering fluticasone propionate (Fp) and …

Background: Wixela Inhub (trademarks of Viatris, Inc.) is a dry powder inhaler (DPI) that
delivers a fixed-dose combination of fluticasone propionate and salmeterol and is approved …